Translation and Validation of the Korean Version of the 39-Item Parkinson's Disease Questionnaire.
- Author:
Do Young KWON
1
;
Jae Woo KIM
;
Hyeo Il MA
;
Tae Beom AHN
;
Jinwhan CHO
;
Phil Hyu LEE
;
Sun Ju CHUNG
;
Joong Seok KIM
;
Jong Sam BAIK
;
Seong Beom KOH
Author Information
- Publication Type:Original Article
- Keywords: Parkinson's disease; quality of life; validation
- MeSH: Cognition; Depression; Humans; Levodopa; Movement Disorders; Parkinson Disease; Quality of Life; Reproducibility of Results; Republic of Korea; Surveys and Questionnaires
- From:Journal of Clinical Neurology 2013;9(1):26-31
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND PURPOSE: The importance of health-related quality of life (HrQoL) has been increasingly emphasized when assessing and providing treatment to patients with chronic, progressive, degenerative disorders. The 39-item Parkinson's disease questionnaire (PDQ-39) is the most widely used patient-reporting scale to assess HrQoL in Parkinson's disease (PD). This study evaluated the validity and reliability of the translated Korean version of the PDQ-39 (K-PDQ-39). METHODS: One hundred and two participants with PD from 10 movement disorder clinics at university-affiliated hospitals in South Korea completed the K-PDQ-39. All of the participants were also tested using the Unified Parkinson's Disease Rating Scale (UPDRS), Korean version of the Mini-Mental State Examination (K-MMSE), Korean version of the Montgomery-Asberg Depression Scale (K-MADS), Epworth Sleepiness Scale (ESS) and non-motor symptoms scale (NMSS). Retests of the K-PDQ-39 were performed over time intervals from 10 to 14 days in order to assess test-retest reliability. RESULTS: Each K-PDQ-39 domain showed correlations with the summary index scores (rS=0.559-0.793, p<0.001). Six out of eight domains met the acceptable standard of reliability (Cronbach's alpha coefficient > or =0.70). The Guttman split-half coefficient value of the K-PDQ-39 summary index, which is an indicator of test-retest reliability, was 0.919 (p<0.001). All of the clinical variables examined except for age, comprising disease duration, levodopa equivalent dose, modified Hoehn and Yahr stage (H&Y stage), UPDRS part I, II and III, mood status (K-MADS), cognition (K-MMSE), daytime sleepiness (ESS) and (NMSS) showed strong correlations with the K-PDQ-39 summary index (p<0.01). CONCLUSIONS: The K-PDQ-39 has been validated for use in the Korean-speaking PD population. The questionnaire is a valid and reliable assessment tool for assessing the HrQoL of Korean PD patients.
